|
|
Vol. 26.11 – 30 June, 2025
|
|
|
|
|
|
|
|
Pediatric ambulatory male participants with a genetic Duchenne muscular dystrophy diagnosis and receiving stable glucocorticoids received a single intravenous low-dose or high-dose fordadistrogene movaparvovec. [Nature Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers reported the first-in-human application of iPSC-derived CD19/BCMA dual-targeting CAR-NK cells in a patient with severe, diffuse cutaneous systemic sclerosis.
[Cell]
|
|
|
|
|
|
Scientists reported a gene-delivery system to generate CAR-T cells in vivo by dosing of a CD8-targeted lipid nanoparticle carrying anti-CD19 CAR mRNA.
[Science]
|
|
|
|
|
|
The authors found that, in addition to OX40 ligand, OX40 can bind to heparan sulfate, a glycosaminoglycan highly expressed on various solid tumor cells.
[Science Translational Medicine]
|
|
|
|
|
|
Investigators showed that an AAV with potent motor neuron transduction delivering Atxn2-targeting miRNAs reduces Atxn2 throughout the central nervous system at doses 40x lower than published work. [Nature Communications]
|
|
|
|
|
|
Researchers screened HLA-DRB3*02:02 patients with melanoma for tumor-specific CD4 T cells and identified robust New York esophageal squamous cell carcinoma 1/HLA-DRB3*02:02 CD4 T cell activity in both peripheral blood and tumor tissue.
[Science Advances]
|
|
|
|
|
|
Investigators described the development of a lentiviral platform based on a novel, detargeted viral fusogen and a membrane-bound targeting moiety to enable in vivo targeted delivery of stably integrating genetic medicines without the need for lymphodepletion.
[Molecular Therapy]
|
|
|
|
|
|
Researchers proposed an original ovarian cancer treatment through the use of two recently developed modified hTERT promoters: the mutated hTERT and the chimeric hTERT-CMV.
[Cancer Gene Therapy]
|
|
|
|
|
|
The authors explored whether AAV mediated gene therapy can achieve durable and functional expression of human FVII in vivo. [Molecular Therapy-Methods & Clinical Development]
|
|
|
|
|
|
|
|
|
Genetically engineered CAR T cells have emerged as a powerful treatment option in patients with B cell malignancies, but neurological adverse effects are common and hamper the success of such therapies.
[Nature Reviews Neurology]
|
|
|
|
|
|
The authors present an overview of CAR technology’s fundamental principles and achievements, focusing on CAR-T cell applications in hepatic viral infections, autoimmune liver disease, and hepatobiliary tumors.
[Journal of Hepatology]
|
|
|
|
|
|
Scientists explore the potential of AAV vectors for gene therapy in ovarian cancer and examine rational gene therapy strategies by categorizing them based on target cells and target genes to determine the most effective approach for ovarian cancer treatment. [Cancer Gene Therapy]
|
|
|
|
|
|
|
|
To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation.
[STEMCELL Technologies]
|
|
|
|
|
|
Professors Craig Simmons and Julie Audet, in collaboration with boutIQ solutions Inc., a University of Toronto (U of T) spinout company specializing in AI-driven media optimization, has been awarded a $421,000 research grant through the Stem Cell Network’s 2025 Research Funding Competition. [U of T Engineering News]
|
|
|
|
|
|
|
|
May 20-23, 2025 Freiburg, Germany
|
|
|
|
|
|
|
|
|
|
|
UMass Chan Medical School – Worcester, Massachusetts, United States
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
|
King’s College London – London, England, United Kingdom
|
|
|
|
|
|
|
KU Leuven – Leuven, Belgium
|
|
|
|
|
|
|
LMU Klinikum – Munich, Germany
|
|
|
|
|
|